|
1 |
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
Enthalten in American journal of cardiovascular drugs 29.6.2019: 1-23
|
|
|
2 |
Zermatt for Gourmets
Thun-Gwatt : Weber, 2010, 2. Aufl.
|
|
|
|
3 |
L' alimentation dans la seconde moitié de la vie
Zurich : Pro Senectute Suisse, 2008, 1. éd.
|
|
|
|
4 |
S'épanouir
Tramelan : CIP Ed., 1999
|
|
|
|
5 |
Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database
Enthalten in Cardiovascular diabetology Bd. 23, 9.1.2024, Nr. 1, date:12.2024: 1-10
|
|
|
|
6 |
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
Enthalten in American journal of cardiovascular drugs Bd. 22, 21.12.2021, Nr. 1, date:1.2022: 111
|
|
|
|
7 |
Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database
Enthalten in Cardiovascular diabetology Bd. 20, 25.11.2021, Nr. 1, date:12.2021: 1-11
|
|
Administration
